| answer text |
<p>The United Kingdom national action plan on antimicrobial resistance (AMR), published
on 24 January 2019, contains the commitment to continue to support research into new
and alternative treatments, vaccines and diagnostic tests.</p><p>The Government has
invested over £350 million in AMR research and development since 2014, including research
funding calls with vaccination in scope, most recently the £32 million capital funding
call lead by the National Institute for Health Research (NIHR), and the Small Business
Research Initiative competition which announced its awards in January 2019. We would
expect to consider the role of vaccines for AMR in future programmatic funding.</p><p>The
UK supports the development of vaccines through UK Aid programmes such as the Global
AMR Innovation Fund (GAMRIF) and the UK Vaccine Network. GAMRIF is a £50 million fund
to support innovative research and development for AMR, for the benefit of people
in low- and middle-income countries, and invests £30 million into preventative measures
in human and animal health, including vaccines for AMR not including tuberculosis
(TB). The fund includes a £1 million work package with the Bacterial Vaccinology Network
which supports early stage research and development around the world to drive the
development and uptake of vaccines for AMR in humans and animals.</p><p>The UK supports
TB vaccine research through the Medical Research Council (MRC), with support to the
European and Developing Countries Clinical Trials Partnership, and through the Joint
Global Health Clinical Trials programme represented by the Department for International
Development (DFID), MRC, NIHR and Wellcome. DFID’s Agriculture research team is supporting
work on bovine TB vaccine development in partnership with the Bill and Melinda Gates
Foundation.</p><p> </p>
|
|
